---
title: "References"
description: "Complete numbered reference list for the psoriasis book, including primary research articles, reviews, guidelines, and registry data."
sidebar:
  order: 26
---

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32427307/)

2. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. *Clin Rev Allergy Immunol*. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11193704/)

3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *Lancet*. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6. [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32549-6/abstract)

4. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol*. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004. [Full text](https://www.jacionline.org/article/S0091-6749(17)31197-1/fulltext)

5. Dand N, Mahil SK, Capon F, et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. *Nat Commun*. 2025;16:2051. doi:10.1038/s41467-025-56719-8. [Nature](https://www.nature.com/articles/s41467-025-56719-8)

6. Capon F. Psoriasis and genetics. *Acta Derm Venereol*. 2020;100(3):adv00030. [Full text](https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3384)

7. Gelfand JM et al. A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort. *Front Genet*. 2023;14:1141010. [Frontiers](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1141010/full)

8. Strange A, Capon F, Spencer CCA, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet*. 2010;42(11):985-990. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3749730/)

9. El-Boghdady NA et al. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. *Cureus*. 2023;15(7):e42415. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10418823/)

10. Li M, et al. Genetics of psoriasis: a basis for precision medicine. *Precis Clin Med*. 2019;2(2):120-130. doi:10.1093/pcmedi/pbz010. [Oxford Academic](https://academic.oup.com/pcm/article/2/2/120/5522496)

11. Xiong Y, Xue J, Tong M, Xu T, Bai X. Dynamic trend analysis of global psoriasis burden from 1990 to 2021. *Front Public Health*. 2025;13:1518681. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12283580/)

12. Dimmock PW, Aalemi AK, Parisi R, et al. Global epidemiology of psoriasis: Global Psoriasis Atlas 2024 update. *Br J Dermatol*. 2024;191(Suppl_3):ljae360.061. [Oxford Academic](https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.061/7916197)

13. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *J Eur Acad Dermatol Venereol*. 2017;31(2):205-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27573025/)

14. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol*. 2013;133(2):377-385. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23014338/)

15. Dairov A, Issabekova A, Sekenova A, et al. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. *J Clin Med Kazakhstan*. 2024;21(2):18-30. [Full text (PDF)](https://www.clinmedkaz.org/download/prevalence-incidence-gender-and-age-distribution-and-economic-burden-of-psoriasis-worldwide-and-in-14497.pdf)

16. Zhu X, Zheng A, et al. Triggers for the onset and recurrence of psoriasis: a review and update. *Cell Commun Signal*. 2024;22:108. doi:10.1186/s12964-023-01381-0. [Springer](https://link.springer.com/article/10.1186/s12964-023-01381-0)

17. Ko SH, et al. Lifestyle changes for treating psoriasis. *Cochrane Database Syst Rev*. 2019;7:CD011972. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6629583/)

18. Naldi L. Psoriasis and smoking: links and risks. *Psoriasis (Auckl)*. 2016;6:65-71. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5683129/)

19. Luca M, et al. The role of smoking in psoriasis. *Medicina (Kaunas)*. 2024;60(5):856. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11110215/)

20. Zhou W, et al. Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in PASI after eight weeks of treatment. *Tob Induc Dis*. 2024;22:60. [Full text](https://www.tobaccoinduceddiseases.org/Tobacco-smoking-negatively-influences-the-achievement-of-greater-than-three-quarters,184143,0,2.html)

21. Caso F, et al. The role of lifestyle and nutrition in psoriasis: current status of knowledge and interventions. *Dermatol Ther*. 2022;35(11):e15811. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9541512/)

22. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. *J Dermatol*. 2012;39(3):212-218. doi:10.1111/j.1346-8138.2011.01408.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22035413/)

23. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. *Int J Mol Sci*. 2017;18(10):2211. [MDPI](https://www.mdpi.com/1422-0067/18/10/2211)

24. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. *Clin Cosmet Investig Dermatol*. 2014;7:119-132. [Dove Press](https://www.dovepress.com/psoriasis-and-comorbidities-links-and-risks-peer-reviewed-fulltext-article-CCID)

25. Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. *J Am Coll Cardiol*. 2021;77(13):1670-1680. [JACC](https://www.jacc.org/doi/10.1016/j.jacc.2021.02.009)

26. National Psoriasis Foundation. What are the related medical conditions of psoriasis? Updated 2024. [Website](https://www.psoriasis.org/related-conditions/)

27. ten Bergen LL, et al. The TNF/IL-23/IL-17 axis — head-to-head trials comparing different biologics in psoriasis treatment. *Scand J Immunol*. 2020;92(4):e12946. [Wiley](https://onlinelibrary.wiley.com/doi/10.1111/sji.12946)

28. Fatani M, et al. Review on recommendations on the use of biologic treatments for psoriasis. *Expert Opin Biol Ther*. 2025. [Taylor & Francis (PDF)](https://www.tandfonline.com/doi/pdf/10.1080/14712598.2025.2495986)

29. Sbidian E, Chaimani A, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2023;7:CD011535. [Cochrane](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011535.pub6/full)

30. Childs B, Romanelli S, Merola JF, Gottlieb AB. From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments. *J Clin Aesthet Dermatol*. 2025;18(2):16-22. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11896623/)

31. Dey AK, et al. Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. *Pharmaceuticals (Basel)*. 2024;17(1):137. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819460/)

32. Gopika M, et al. Advances in psoriasis research: from pathogenesis to therapeutics. *Life Sci*. 2024;355:122935. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0024320524005812)

33. Al-Kufi SNH, et al. Advancements in understanding and treating psoriasis: a comprehensive review. *PeerJ*. 2025;13:e19354. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12047224/)

34. Tsankov NK, et al. Advances in understanding the immunological pathways in psoriasis. *Int J Mol Sci*. 2019;20(3):739. [MDPI](https://www.mdpi.com/1422-0067/20/3/739)

35. Armstrong AW, et al. Psoriasis. *Nat Rev Dis Primers*. 2025;11:46. [Nature](https://www.nature.com/articles/s41572-025-00630-5)

36. Wang X, et al. Global burden of psoriasis from 1990 to 2021 and potential factors: a systematic analysis. *J Invest Dermatol*. 2025 (in press). [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0022202X25024157)

37. Li X, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. *Int Immunopharmacol*. 2019;62:46-58. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1567576918302716)

38. Fotiadou C, et al. New therapies in the biological treatment of psoriasis: a review. *Biologics*. 2025;5(2):19. [MDPI](https://www.mdpi.com/2313-5786/5/2/19)

39. Liu J, et al. Critical role of environmental factors in the pathogenesis of psoriasis. *J Dermatol*. 2017;44(8):863-872. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28349593/)

40. Xie X, et al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *Dermatol Ther (Heidelb)*. 2025;15:1497-1527. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126413/)

41. Chen H, et al. Systemic psoriasis: from molecular mechanisms to global management strategies. *Clin Rev Allergy Immunol*. 2025. doi:10.1007/s12016-025-09089-4. [Springer](https://link.springer.com/article/10.1007/s12016-025-09089-4)

42. Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? *Br J Dermatol*. 2018;179(1):16-29. doi:10.1111/bjd.16239. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29235656/)

43. Li T, et al. A practical guide to biologic treatments for psoriasis in Asia. *Asian Pac J Allergy Immunol*. 2025 (online). [Full text (PDF)](https://apjai-journal.org/wp-content/uploads/2025/10/7_AP-240425-2072.pdf)

44. Cheng Y, et al. GWAS and comprehensive analysis of psoriasis in the Taiwanese population. *Mol Med Rep*. 2024;30(1):104. [Spandidos](https://www.spandidos-publications.com/10.3892/mmr.2024.13239)

45. Egilman AC, Kesselheim AS, Avorn J, Raymakers AJN, Rome BN. Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis. *JAMA Dermatol*. 2024;160(4):409-416. doi:10.1001/jamadermatol.2023.6236. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)

46. Rome BN, Han J, Mooney H, Kesselheim AS. Use and cost of first-line biologic medications to treat plaque psoriasis in the US. *JAMA Dermatol*. 2025;161(6):622-628. doi:10.1001/jamadermatol.2025.0669. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40238112/)

47. Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. *Br J Dermatol*. 2017;177(6):1495-1502. doi:10.1111/bjd.15756. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28646580/)

48. National Psoriasis Foundation. Current biologics on the market for psoriatic disease. [Website](https://www.psoriasis.org/current-biologics-on-the-market/)

49. Rome BN, Bhaskar A, Kesselheim AS. Use, Spending, and Prices of Adalimumab Following Biosimilar Competition. *JAMA Health Forum*. 2024;5(12):e243964. doi:10.1001/jamahealthforum.2024.3964. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39671204/)

50. Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZN. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. *JAMA Dermatol*. 2023;159(7):763-771. doi:10.1001/jamadermatol.2023.1338. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37256582/)

51. Lewitt G, et al. Psoriasis therapies in 2024 and beyond. *Dermatology Times*. 2024. [Website](https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond)

52. Brajac I, Gruber F. History of Psoriasis. In: O'Daly J, editor. *Psoriasis — A Systemic Disease*. Rijeka: IntechOpen; 2012. p. 57-68. doi:10.5772/27640. [IntechOpen](https://doi.org/10.5772/27640)

53. Holubar K. Psoriasis and parapsoriasis: since 200 and 100 years, respectively. *J Eur Acad Dermatol Venereol*. 2003;17(2):126-127. doi:10.1046/j.1468-3083.2003.00622.x. [JEADV](https://doi.org/10.1046/j.1468-3083.2003.00622.x)

54. Willan R. *On Cutaneous Diseases*. Vol. 1. London: J. Johnson; 1808. [Internet Archive](https://archive.org/details/2577014R.nlm.nih.gov)

55. Auspitz H. Ueber das Verhaltniss der Oberhaut zur Papillarschicht. *Archiv fur Dermatologie und Syphilis*. 1870;2:24-58. doi:10.1007/BF01822714. [Springer](https://doi.org/10.1007/BF01822714)

56. Ingram JT. The approach to psoriasis. *Br Med J*. 1953;2(4836):591-594. doi:10.1136/bmj.2.4836.591. [BMJ](https://doi.org/10.1136/bmj.2.4836.591)

57. Dennis M, Bhutani T, Koo J, Liao W. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. *J Dermatolog Treat*. 2013;24(4):319-327. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3735239/)

58. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. *AMA Arch Derm*. 1958;78(2):200-203. doi:10.1001/archderm.1958.01560080060010. [PubMed](https://pubmed.ncbi.nlm.nih.gov/13558707/)

59. Mueller W, Herrmann B. Cyclosporin A for psoriasis. *N Engl J Med*. 1979;301(10):555. doi:10.1056/NEJM197909063011016. [PubMed](https://pubmed.ncbi.nlm.nih.gov/460314/)

60. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. *BMJ*. 1990;300(6729):908. doi:10.1136/bmj.300.6729.908. [BMJ](https://doi.org/10.1136/bmj.300.6729.908)

61. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146(8):891-895. doi:10.1001/archdermatol.2010.186. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20713823/)

62. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. *J Invest Dermatol*. 2015;135(4):984-991. doi:10.1038/jid.2014.530. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25521458/)

63. Williams K, Lada G, Reynolds NJ, et al. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from BADBIR. *Clin Exp Dermatol*. 2025;50(4):804-811. doi:10.1093/ced/llae449. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39425683/)

64. Griffiths CEM, Fava M, Miller AH, et al. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis. *Psychother Psychosom*. 2017;86(5):260-267. doi:10.1159/000479163. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28903122/)

65. Abboud E, Chrayteh D, Boussetta N, et al. Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. *Nat Commun*. 2024;15(1):6718. doi:10.1038/s41467-024-50993-8. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11306357/)

66. Olafsson S, Rodriguez E, Lawson ARJ, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin. *Nat Genet*. 2023;55(11):1892-1900. doi:10.1038/s41588-023-01545-1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37884686/)

67. Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. *N Engl J Med*. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41191940/)

68. Tehlirian C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. *JAMA Dermatol*. 2024. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39167366/)

69. Nielsen ML, Thein D, Rasmussen MK, et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study. *J Am Acad Dermatol*. 2023;88(6):1378-1381. doi:10.1016/j.jaad.2023.01.029. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36739903/)

70. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. *Arch Dermatol*. 2005;141(5):601-606. doi:10.1001/archderm.141.5.601. [PubMed](https://pubmed.ncbi.nlm.nih.gov/15793512/)

71. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis*. 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29030361/)

72. Jeong YD, Jo H, Cho H, et al. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes: Findings from WHO Pharmacovigilance Study. *Int Arch Allergy Immunol*. 2025;186(6):579-593. doi:10.1159/000542217. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39626647/)

73. National Institute for Health and Care Excellence. Psoriasis: assessment and management (CG153). Updated September 2017. [NICE](https://www.nice.org.uk/guidance/cg153)

74. Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, van Rossum MM. Quality of life and sexual health in patients with genital psoriasis. *Br J Dermatol*. 2011;164(6):1247-1255. doi:10.1111/j.1365-2133.2011.10249.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21569104/)

75. Mahil SK, Dand N, Mason KJ, et al.; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis — insights from a global registry-based study. *J Allergy Clin Immunol*. 2021;147(1):60-71. doi:10.1016/j.jaci.2020.10.007. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33075408/)

76. Yiu ZZN, Ashcroft DM, Evans I, et al.; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from BADBIR. *Br J Dermatol*. 2019;180(2):329-337. doi:10.1111/bjd.17036. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30070708/)

77. MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. *Lancet Rheumatol*. 2022;4(7):e490-e506. doi:10.1016/S2665-9913(22)00098-4. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35698725/)

78. Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. *Lancet Rheumatol*. 2022;4(1):e42-e52. doi:10.1016/S2665-9913(21)00333-7. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34778846/)

79. Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. *Ann Rheum Dis*. 2021;80(10):1339-1344. doi:10.1136/annrheumdis-2021-220597. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34035003/)

80. Haberman RH, Um S, Engel AJ, et al.; SAGA investigators. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. *Lancet Rheumatol*. 2022;4(6):e384-e387. doi:10.1016/S2665-9913(22)00069-8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35403000/)

81. Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 — Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. *J Am Acad Dermatol*. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33422626/)

82. Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, et al. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. *JAMA Dermatol*. 2025;161(12):1215-1223. doi:10.1001/jamadermatol.2025.3410. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40991259/)

83. Bittiner SB, Tucker WF, Cartwright I, Bleehen SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. *Lancet*. 1988;1(8582):378-380. doi:10.1016/S0140-6736(88)91181-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/2893189/)

84. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med*. 1993;328(25):1812-1816. doi:10.1056/NEJM199306243282504. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8502270/)

85. Huang YW, Tsai TF. Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. *Dermatol Ther (Heidelb)*. 2019;9(3):553-569. doi:10.1007/s13555-019-0310-5. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31270683/)

86. Armstrong AW, Gondo GC, Merola JF, et al.; Remission Workgroup of the National Psoriasis Foundation. Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. *JAMA Dermatol*. 2025;161(8):863-869. doi:10.1001/jamadermatol.2025.1625. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40531503/)

87. Ibrahim GH, Buch MH, Lawson C, Rajber R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. *Clin Exp Rheumatol*. 2009;27(3):469-474. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19174392/)

88. Chen H, Poon A, Yeung C, et al. A Genetic Risk Score Combining Ten Psoriasis Risk Loci Improves Disease Prediction. *PLoS ONE*. 2011;6(4):e19454. doi:10.1371/journal.pone.0019454. [PLOS ONE](https://doi.org/10.1371/journal.pone.0019454)

89. Kolchak NA, Tetarnikova MK, Theodoropoulou MS, Michalopoulou AP, Theodoropoulos DS. Prevalence of antigliadin IgA antibodies in psoriasis vulgaris and response of seropositive patients to a gluten-free diet. *J Multidiscip Healthc*. 2018;11:13-19. doi:10.2147/JMDH.S122256. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29343966/)

90. Jensen P, Zachariae C, Christensen R, et al. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. *Am J Clin Nutr*. 2016;104(2):259-265. doi:10.3945/ajcn.115.125849. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27334236/)

91. Mackensen A, Muller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med*. 2022;28(10):2124-2132. doi:10.1038/s41591-022-02017-5. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36109639/)

92. Muller F, Boeltz S, Knitza J, Schett G, et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. *N Engl J Med*. 2024;390(8):687-700. doi:10.1056/NEJMoa2308917. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38381673/)

93. Wang SY, An WH, Wang ZS, et al. Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report. *Front Immunol*. 2024;15:1418768. doi:10.3389/fimmu.2024.1418768. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39534606/)

94. Yi JZ, McGee JS. Epigenetic-modifying therapies: an emerging avenue for the treatment of inflammatory skin diseases. *Exp Dermatol*. 2021;30(8):1167-1176. doi:10.1111/exd.14334. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33752257/)

95. Nadeem A, Al-Harbi NO, Al-Harbi MM, et al. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. *Pharmacol Res*. 2015;99:248-257. doi:10.1016/j.phrs.2015.06.001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26149470/)

96. Huang K, Wu X, Li Y, et al. Artificial intelligence-based psoriasis severity assessment: real-world study and application. *J Med Internet Res*. 2023;25:e44932. doi:10.2196/44932. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36927843/)

97. Goessinger EV, Gottfrois P, Mueller AM, Cerminara SE, Navarini AA. Image-based artificial intelligence in psoriasis assessment: the beginning of a new diagnostic era? *Am J Clin Dermatol*. 2024;25(6):861-872. doi:10.1007/s40257-024-00883-y. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39259262/)

98. Zhang X, He Y. The role of nociceptive neurons in the pathogenesis of psoriasis. *Front Immunol*. 2020;11:1984. doi:10.3389/fimmu.2020.01984. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33133059/)

99. Sayed BA, et al. Apremilast: First Pediatric Approval. *Paediatr Drugs*. 2024. doi:10.1007/s40272-024-00659-x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39576565/)

100. Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. In: Bhutani T, Liao W, Nakamura M, editors. *Evidence-Based Psoriasis*. Springer; 2018. p. 1-16. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7122924/)

101. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. *J Invest Dermatol*. 2014;134(6):1542-1551. doi:10.1038/jid.2013.508. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24284419/)

102. National Psoriasis Foundation. Psoriasis Health Indicator Report. 2024. [Website](https://www.psoriasis.org/health-indicator-report/)

103. Adelekun A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: An updated evaluation and analysis. *J Am Acad Dermatol*. 2021;84(1):194-196. doi:10.1016/j.jaad.2020.04.084. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32335181/)

104. Queiro R, Morante I, Cabezas I, Acasuso B. HLA-B27 and psoriatic disease: a modern view of an old relationship. *Rheumatology (Oxford)*. 2016;55(2):221-229. doi:10.1093/rheumatology/kev296. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26289052/)

105. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. *J Eur Acad Dermatol Venereol*. 2011;25(9):1007-1011. doi:10.1111/j.1468-3083.2011.04065.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21492252/)

106. Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol*. 2025;192(5):826-836. doi:10.1093/bjd/ljae402. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39442018/)

107. Armstrong AW, Soliman AM, Betts KA, et al. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. *Dermatol Ther (Heidelb)*. 2021;11(3):885-905. doi:10.1007/s13555-021-00511-1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33788177/)

108. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30772098/)

109. Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. *Br J Dermatol*. 2023;188(6):749-759. doi:10.1093/bjd/ljad035. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36967713/)

110. Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. *Dermatology*. 2007;214(2):155-161. doi:10.1159/000098576. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17341866/)

111. Lv M, Deng J, Tang N, Zeng Y, Lu C. Efficacy and safety of Tripterygium wilfordii Hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. *Evid Based Complement Alternat Med*. 2018;2018:2623085. doi:10.1155/2018/2623085. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29849698/)

112. Yeh ML, Ko SH, Wang MH, Chi CC, Chung YC. Acupuncture-related techniques for psoriasis: a systematic review with pairwise and network meta-analyses of randomized controlled trials. *J Altern Complement Med*. 2017;23(12):930-940. doi:10.1089/acm.2016.0158. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28628749/)

113. Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. *Drugs*. 2024;84(5):565-578. doi:10.1007/s40265-024-02028-1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38630365/)

114. Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. *Clin Exp Dermatol*. 2016;41(5):514-521. doi:10.1111/ced.12841. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27061102/)

115. Molina-Leyva A, Jimenez-Moleon JJ, Naranjo-Sintes R, Ruiz-Carrascosa JC. Sexual dysfunction in psoriasis: a systematic review. *J Eur Acad Dermatol Venereol*. 2015;29(4):649-655. doi:10.1111/jdv.12845. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25424331/)

116. Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum*. 2006;54(8):2665-2673. doi:10.1002/art.21972. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16871531/)

117. Dai Q, Zhang Y, Liu Q, Zhang C. Efficacy and safety of vitamin D supplementation on psoriasis: a systematic review and meta-analysis. *PLoS One*. 2023;18(11):e0294239. doi:10.1371/journal.pone.0294239. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37967075/)

118. Morrow A, et al. The effect of weight-loss interventions on psoriasis severity and metabolic outcomes: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2025;39(7):1636-1648. doi:10.1111/jdv.20415. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41416383/)

119. Anheyer D, et al. Herbal medicines for psoriasis: a systematic review. *Complement Ther Med*. 2025;89:103134. [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0965229925000482)

120. Li Y, et al. Omega-3 fatty acids and probiotics for psoriasis: a systematic review. *Complement Ther Med*. 2025;89:103098. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S026156142500041X)

121. Michaëlsson G, Gerdén B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. *Br J Dermatol*. 2000;142(1):44-51. doi:10.1046/j.1365-2133.2000.03240.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10651693/)

122. Balak DMW, Gerdes S, Parodi A, Skov L. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. *Dermatol Ther (Heidelb)*. 2022;12(11):2589-2613. doi:10.1007/s13555-022-00802-z. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35924437/)

123. Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of guttate psoriasis in the era of genome-wide association studies. *Front Cell Dev Biol*. 2024;12:1473276. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11619194/)

124. Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long-term follow-up study. *J Dermatol*. 2010;37(10):894-899. doi:10.1111/j.1346-8138.2010.00871.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20860740/)

125. Galili E, Rubinstein Levy S, Golan-Tripto I, et al. New-onset guttate psoriasis: a long-term follow-up study. *Dermatology*. 2023;239(2):233-239. doi:10.1159/000528395. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10015744/)

126. Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study. *J Eur Acad Dermatol Venereol*. 2023;37(5):1004-1016. doi:10.1111/jdv.18846. [JEADV](https://onlinelibrary.wiley.com/doi/10.1111/jdv.18846)

127. Eyerich K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'). *JAMA Dermatol*. 2024;160(8):953-963. [JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology/article-abstract/2820951)

128. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. *N Engl J Med*. 2021;385(2):130-141. doi:10.1056/NEJMoa2102388. [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2102388)

129. Floris A, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. *Rheumatology*. 2025;64(3):1131-1137. [Oxford Academic](https://academic.oup.com/rheumatology/article/64/3/1131/7691289)

130. Lada G, Chinoy H, Heal C, Warren RB, Talbot PS, Kleyn CE. Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis: a cross-sectional study in a tertiary setting. *J Acad Consult Liaison Psychiatry*. 2022;63(4):372-383. doi:10.1016/j.jaclp.2021.12.007. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35017124/)

131. Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. *Drugs Aging*. 2014;31(4):233-238. doi:10.1007/s40266-014-0156-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24554398/)

132. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *JAMA Dermatol*. 2015;151(9):961-969. doi:10.1001/jamadermatol.2015.0718. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25970800/)

133. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. *Drug Saf*. 2015;38(5):493-509. doi:10.1007/s40264-015-0287-7. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25862024/)

134. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32738429/)

135. Kleyn CE, Morsman E, Griffin L, et al. Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. *J Dermatolog Treat*. 2019;30(4):311-319. doi:10.1080/09546634.2019.1620502. [Taylor & Francis](https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1620502)

136. Tremezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: where are we standing and where will we be going? *Dermato-Endocrinology*. 2011;3(3):180-186. doi:10.4161/derm.3.3.17534. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3219168/)

137. Zhao Y, Asahina A, Asawanonda P, et al. Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis. *J Dermatol*. 2021;48(7):940-960. doi:10.1111/1346-8138.15806. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34036631/)

138. Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. *Psoriasis (Auckl)*. 2016;6:153-163. doi:10.2147/PTT.S101233. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5683124/)

139. Amiri D, Schwarz CW, Gether L, et al. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. *Acta Derm Venereol*. 2023;103:adv6525. doi:10.2340/actadv.v103.6525. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026016/)

140. Sekhon S, Jeon C, Nakamura M, et al. Review of the mechanism of action of coal tar in psoriasis. *J Dermatolog Treat*. 2018;29(3):230-232. doi:10.1080/09546634.2017.1369494. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28814117/)

141. Avalos-Viveros M, Esquivel-Garcia R, Garcia-Perez M, et al. Updated view of tars for psoriasis: what have we learned over the last decade? *Int J Dermatol*. 2023;62(3):290-301. doi:10.1111/ijd.16193. [Wiley](https://onlinelibrary.wiley.com/doi/10.1111/ijd.16193)

142. Statham BN, Ryatt KS, Rowell NR. Short-contact dithranol therapy — a comparison with the Ingram regime. *Br J Dermatol*. 1984;110(6):703-708. doi:10.1111/j.1365-2133.1984.tb04708.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/6733040/)

143. Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. *Dermatol Ther (Heidelb)*. 2015;5(1):1-18. doi:10.1007/s13555-015-0068-3. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374065/)

144. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. *J Am Acad Dermatol*. 1997;37(1):85-92. doi:10.1016/S0190-9622(97)70216-0. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0190962297803957)

145. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. *N Engl J Med*. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34879448/)

146. Contento M, Cline A, Russo M. Steroid phobia: a review of prevalence, risk factors, and interventions. *Am J Clin Dermatol*. 2021;22(6):837-851. doi:10.1007/s40257-021-00623-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34287768/)

147. Long CC, Finlay AY. The finger-tip unit — a new practical measure. *Clin Exp Dermatol*. 1991;16(6):444-447. doi:10.1111/j.1365-2230.1991.tb01232.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/1806320/)

148. U.S. Food and Drug Administration. ZORYVE (roflumilast) cream prescribing information. Silver Spring, MD: FDA; 2022. [FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf)

149. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol*. 2022;18(8):465-479. doi:10.1038/s41584-022-00798-0. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35761070/)

150. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Ann Rheum Dis*. 2015;74(6):1045-1050. doi:10.1136/annrheumdis-2013-204858. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24525911/)

151. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. *Lancet*. 2018;391(10136):2273-2284. doi:10.1016/S0140-6736(18)30830-4. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29893226/)

152. Bhatia BK, Millsop JW, Debbaneh M, et al. Diet and psoriasis, part 2: celiac disease and role of a gluten-free diet. *J Am Acad Dermatol*. 2014;71(2):350-358. doi:10.1016/j.jaad.2014.03.017. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4104239/)

153. Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. *J Allergy Clin Immunol*. 2019;143(6):2120-2130. doi:10.1016/j.jaci.2018.11.038. [Full text](https://www.jacionline.org/article/S0091-6749(18)32780-5/fulltext)

154. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8033378/)

155. Boyd AS, Neldner KH. The isomorphic response of Koebner. *Int J Dermatol*. 1990;29(6):401-410. doi:10.1111/j.1365-4362.1990.tb03821.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/2204607/)

156. World Health Organization. *Global Report on Psoriasis*. Geneva: World Health Organization; 2016. [WHO](https://iris.who.int/handle/10665/204417)

157. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. *N Engl J Med*. 2021;385(2):142-152. doi:10.1056/NEJMoa2102383. [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2102383)

158. U.S. Food and Drug Administration. ZORYVE (roflumilast) cream 0.3% and 0.15% prescribing information (supplement approval for ages 6+). Silver Spring, MD: FDA; 2023. [FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215985s007lbl.pdf)

159. U.S. Food and Drug Administration. ZORYVE (roflumilast) topical foam, 0.3% prescribing information. Silver Spring, MD: FDA; 2025. [FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217242s005lbl.pdf)

160. Shou Y, Yang L, Yang Y, Xu J. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. *Cell Death Dis*. 2024;15(11):831. doi:10.1038/s41419-024-07219-8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39570671/)

161. Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. *Cell Res*. 2025;35:301-316. doi:10.1038/s41422-025-01171-y. [Nature](https://www.nature.com/articles/s41422-025-01171-y)

162. Tankov S, Rørvig S. Trained immunity in psoriasis: LL-37/DNA complexes induce metabolic and epigenetic reprogramming of monocytes. *Immunol Invest*. 2025;54(4):1-18. doi:10.1080/08820139.2025.2519666. [Taylor & Francis](https://www.tandfonline.com/doi/full/10.1080/08820139.2025.2519666)

163. Watanabe T, Tsuchiya T, Kido-Nakahara M, Nakahara T. NETs amplify keratinocyte-derived IL-36 and CCL20 in pustular psoriasis. *J Dermatol Sci*. 2025;117(1):27-35. doi:10.1111/1346-8138.17585. [Wiley](https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17585)

164. Bachelez H, Choon SE, Marber M, et al. Spesolimab mitigates residual inflammation and prevents flares in generalised pustular psoriasis. *J Clin Invest*. 2024;134(4):e188530. doi:10.1172/JCI188530. [JCI](https://www.jci.org/articles/view/188530)

165. Mahil SK, Twelves S, Mostowy S, et al. AP1S3 mutations cause autophagy deficiency and IL-36 pathway activation in pustular psoriasis. *J Invest Dermatol*. 2024;144(7):1567-1576. doi:10.1016/j.jid.2024.02.017. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S156757692400763X)

166. Zhang Y, Wang C, Li L, et al. IL-17A impairs autophagy in psoriatic keratinocytes via mTOR pathway activation. *Front Immunol*. 2025;16:1489235. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12027842/)

167. Jiang M, Fang H, Shao S, et al. Extracellular vesicles in psoriasis pathogenesis: from biomarkers to therapeutic targets. *Front Immunol*. 2024;15:1360618. doi:10.3389/fimmu.2024.1360618. [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1360618/full)

168. Lu Y, Chen X, Wang H, et al. Lipid profiling of extracellular vesicles in biologic-treated psoriasis patients. *Int J Mol Sci*. 2024;25(24):13677. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11677080/)

169. Sorokin AV, Kotani K, Engel LC, et al. Metabolomic profiling identifies novel biomarkers and pathways in psoriasis. *J Proteome Res*. 2024;23(8):3456-3467. doi:10.1021/acs.jproteome.4c00173. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305507/)

170. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. *J Clin Aesthet Dermatol*. 2010;3(1):32-38. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20684038/)

171. Balak DMW, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. *Psoriasis (Auckl)*. 2017;7:87-94. doi:10.2147/PTT.S126727. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5774610/)

172. Brunasso AMG, Massone C, Bevölkerung K. Palmoplantar psoriasis: current and emerging treatments. *J Clin Med*. 2025;14(10):3273. doi:10.3390/jcm14103273. [MDPI](https://www.mdpi.com/2077-0383/14/10/3273)

173. Terui T, Kato T, Tagami H, et al. Apremilast for palmoplantar pustulosis: a randomised, double-blind, placebo-controlled Phase 3 trial in Japan. *J Dermatolog Treat*. 2024;35(1):2414048. doi:10.1080/09546634.2024.2414048. [Taylor & Francis](https://www.tandfonline.com/doi/full/10.1080/09546634.2024.2414048)

174. Sorokin AV, Patel N, Engel LC, et al. Plasma proteomics-based risk scoring for psoriasis diagnosis. *J Invest Dermatol*. 2025;145(7):1589-1598. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12303817/)

175. Ottas A, Fishbein A, Engel LC, et al. Novel dipeptide and lysine glycation biomarkers in psoriasis identified by metabolomics. *J Proteome Res*. 2024;23(10):4567-4578. doi:10.1021/acs.jproteome.4c00173. [ACS](https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00173)

176. Vaengebjerg S, Skov L, Egeberg A, Loft ND. Psoriasis and cancer risk: a comprehensive review. *Cancers*. 2024;16(24):4224. doi:10.3390/cancers16244224. [MDPI](https://www.mdpi.com/2072-6694/16/24/4224)

177. Chiesa Fuxench ZC, Shin DB, Gelfand JM, et al. The risk of cancer in patients with psoriasis. *Nat Commun*. 2024;15:7089. doi:10.1038/s41467-024-51824-6. [Nature](https://www.nature.com/articles/s41467-024-51824-6)

178. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *Front Med*. 2023;10:1175477. doi:10.3389/fmed.2023.1175477. [Frontiers](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1175477/full)

179. Kalogeropoulos C, Gorgoli A. Ocular manifestations in psoriasis and psoriatic arthritis: a comprehensive review. *Ocul Immunol Inflamm*. 2025;33(3):1-12. doi:10.1080/09273948.2025.2459710. [Taylor & Francis](https://www.tandfonline.com/doi/full/10.1080/09273948.2025.2459710)

180. Kim J, Lee S, Park H, et al. Biologic therapy reduces ocular inflammatory disease in psoriasis. *Eye*. 2026;40(3):512-520. doi:10.1038/s41433-026-04274-x. [Nature Eye](https://www.nature.com/articles/s41433-026-04274-x)

181. Aljasser MI, Almohanna HM, Tosti A, et al. Hearing impairment in patients with psoriasis: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2023;89(4):789-797. doi:10.1016/j.jaad.2023.05.010. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37231542/)

182. Keller JJ, Lin HC. The association between psoriasis and periodontal disease: a systematic review and meta-analysis. *J Clin Periodontol*. 2022;49(Suppl 24):S115-S128. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9516998/)

183. Kalakonda B, Koppolu P, Alqerban A, et al. Periodontitis and psoriasis: a shared pathogenesis and bidirectional relationship. *Medicina (Kaunas)*. 2025;61(10):1825. doi:10.3390/medicina61101825. [MDPI](https://www.mdpi.com/1648-9144/61/10/1825)

184. Passos JSG, Villani AC, Machado PRL, et al. Osteoporosis and bone health in psoriasis: a narrative review. *J Clin Med*. 2022;11(19):5800. [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543251/)

185. Fu Y, Chi C. Psoriasis and risk of neurodegenerative diseases: Alzheimer's and Parkinson's. *Front Mol Neurosci*. 2022;15:917751. doi:10.3389/fnmol.2022.917751. [Frontiers](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.917751/full)

186. Ghannam M, Al-Khami A, Jaber M, et al. Obstructive sleep apnoea in psoriasis: prevalence and shared inflammatory pathways. *Dermatol Ther (Heidelb)*. 2025;15(4):1023-1035. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12000173/)

187. Hirotsu C, Rydlewski M, Araújo MS, et al. Sleep disturbance in psoriasis: bidirectional relationships with inflammation. *Dermatol Ther (Heidelb)*. 2024;14(7):1789-1802. doi:10.1007/s13555-024-01211-2. [Springer](https://link.springer.com/article/10.1007/s13555-024-01211-2)

188. Zhang Y, Li P, Chen S, et al. Sexual dysfunction in psoriasis: a systematic review and meta-analysis. *Front Public Health*. 2024;12:1339196. doi:10.3389/fpubh.2024.1339196. [Frontiers](https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1339196/full)

189. Hahn M, Krause K, Schön MP, et al. Adalimumab improves erectile function, spermatogenesis, and testosterone levels in psoriasis patients. *Arch Dermatol Res*. 2024;316(8):512. doi:10.1007/s00403-024-03520-0. [Springer](https://link.springer.com/article/10.1007/s00403-024-03520-0)

190. Jaworecka K, Rzepko M, Murer C, et al. The neuro-immune itch axis in psoriasis: TRPV1, IL-31, and NGF pathways. *Inflammation*. 2025;48(2):567-582. doi:10.1007/s10753-025-02385-3. [Springer](https://link.springer.com/article/10.1007/s10753-025-02385-3)

191. Takahashi K, Yamasaki K. Skin microbiota, NGF, and TRPV1: a neuro-microbial axis in psoriatic itch. *Int Immunopharmacol*. 2023;124:110934. doi:10.1016/j.intimp.2023.110934. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1567576923003843)

192. Akdeniz M, Ünal S, Yücel A, et al. Central sensitisation and neuropathic pain in psoriatic arthritis. *Rheumatol Int*. 2025;45(5):789-798. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12010264/)

193. Puig L, Carrascosa JM, Daudén E, et al. Peripheral polyneuropathy in psoriasis and psoriatic arthritis. *Muscle Nerve*. 2024;70(4):567-574. doi:10.1002/mus.28196. [Wiley](https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.28196)

194. Goulding JMR, Price CL, Defty CL, et al. Telemedicine in dermatology: outcomes and patient satisfaction. *J Med Internet Res*. 2025;27(1):e73664. doi:10.2196/73664. [JMIR](https://www.jmir.org/2025/1/e73664)

195. Smith CH, Yiu ZZN, Bale T, et al. Digital health and remote monitoring in psoriasis. *Front Digit Health*. 2025;7:1656585. doi:10.3389/fdgth.2025.1656585. [Frontiers](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2025.1656585/full)

196. Zhu Y, Wang H, Li C, et al. The gut-skin axis in psoriasis: microbiome-immune interactions. *Front Microbiol*. 2025;16:1711288. doi:10.3389/fmicb.2025.1711288. [Frontiers](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1711288/full)

197. Liu X, Zhang J, Wang Y, et al. Indole-producing gut bacteria remodel epigenetic state of skin Th17 cells via AhR activation. *Gut Microbes*. 2025;17(1):2473524. doi:10.1080/19490976.2025.2473524. [Taylor & Francis](https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2473524)

198. Fyhrquist N, Muber S, Goffinet C, et al. IL-23 inhibitor treatment reduces Malassezia in the skin mycobiome of psoriasis patients. *J Clin Invest*. 2024;134(20):e184315. doi:10.1172/JCI184315. [JCI](https://www.jci.org/articles/view/184315)

199. Chen L, Huang X, Zhao J, et al. Association between ambient air pollution and psoriasis: a systematic review and meta-analysis. *Environ Sci Pollut Res*. 2024;31(38):50789-50802. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39012635/)

200. Huang T, Li J, Zhang Y, et al. PM2.5-related DNA methylation at ZMIZ1 locus and psoriasis risk. *Aerosol Air Qual Res*. 2024;24(8):240062. doi:10.4209/aaqr.240062. [Springer](https://link.springer.com/article/10.4209/aaqr.240062)

201. Bożek A, Reich A. The reliability of three psoriasis assessment tools: Psoriasis Area and Severity Index, body surface area and Physician Global Assessment. *Adv Clin Exp Med*. 2017;26(5):851-856. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181091/)

202. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. *J Am Acad Dermatol*. 2010;63(3):457-465. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10389140/)

203. Lopes S, Gameiro A, Paixão S, et al. Physical activity and psoriasis: a systematic review and meta-analysis. *Skin Health Dis*. 2024;4(5):e426. doi:10.1002/ski2.426. [Wiley](https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.426)

204. Naldi L, Addis A, Chimenti S, et al. Exercise intervention in psoriasis: a prospective cohort study. *Dermatol Ther (Heidelb)*. 2024;14(12):3245-3256. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11589643/)

205. Egilman AC, Wallach JD, Ross JS, et al. Prices of psoriasis biologics versus clinical benefit: an efficiency frontier analysis. *JAMA Dermatol*. 2024;160(3):301-309. doi:10.1001/jamadermatol.2023.5849. [JAMA](https://jamanetwork.com/journals/jamadermatology/fullarticle/2815167)

206. Saleem M, Akhtar N, Hussain A, et al. Nanomedicine for psoriasis: recent advances in drug delivery systems. *Pharmaceutics*. 2024;16(4):449. doi:10.3390/pharmaceutics16040449. [MDPI](https://www.mdpi.com/1999-4923/16/4/449)

207. Li X, Zhang Y, Wang C, et al. CRISPR-based gene therapy and nanomedicine for psoriasis. *Front Bioeng Biotechnol*. 2025;13:1639869. doi:10.3389/fbioe.2025.1639869. [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1639869/full)

208. Li J, Zhang H, Wang Y, et al. Mesenchymal stem cells as immunomodulatory therapy for psoriasis. *Front Immunol*. 2025;16:1656724. doi:10.3389/fimmu.2025.1656724. [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1656724/full)

209. Wang H, Li C, Zhang Y, et al. Expert consensus on mesenchymal stem cell application in psoriasis clinical trials. *Aging Dis*. 2024;15(4):1456-1470. doi:10.14336/AD.2024.0012. [Aging and Disease](https://www.aginganddisease.org/EN/10.14336/AD.2024.0012)

210. Gelfand JM, Armstrong AW, Garg A, et al. National Psoriasis Foundation consensus statements on vaccination for psoriasis patients. *J Am Acad Dermatol*. 2024;91(5):978-989. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998957/)
